106results about "Osteogenic factor" patented technology

The invention relates to the field of bioengineering, in particular to a bilateral cleft lip mouse model based on Pitx2-Cre conditional knockout of Bmp4 as well as a construction method and application of the bilateral cleft lip mouse model. The invention aims to construct a stable bilateral cleft lip mouse model. Experiments find that the Bmp4 gene is expressed in the epithelium of the frontal nose process and the maxillary process at the early lip stage in E9.25. The spatio-temporal expression mode of the Pitx2 gene in the early primordium epithelium is highly consistent with the spatio-temporal expression mode of the Bmp4 gene. Based on this, the inventor constructs a Bmp4 gene knockout model driven by an endogenous Pitx2 gene promoter, and finds that the mouse model shows a 100% bilateral cleft lip phenotype. Compared with the reported Netin-Cre, the Nestin-Cre has the advantages that the Nestin The bilateral cleft lip model constructed by the method is more stable, can better represent genetic diseases of human cleft lip, and has important research significance.

The invention belongs to the technical field of medicines, and particularly relates to application of BMP9 as an intervention target in preparation of a medicine for treating diabetic nephropathy. More specifically, the invention provides application of a BMP9 accelerant in preparation of a medicine for preventing and / or treating diabetic nephropathy. The BMP9 accelerant is a substance shown in the following (i) or (ii): (i) a substance for increasing the content of BMP9 in a subject; (ii) a substance that increases BMP9 activity in a subject. According to the invention, a DKD mouse model is constructed, and liver RNA-seq sequencing is carried out, such that a differential expression gene BMP9 exists between a normal mouse and a DKD mouse. It is found that BMP9 can be used as a new target for prevention and treatment of DKD and has important theoretical significance and potential clinical application value.

The present invention pertains to periostin compounds for use in the prevention and treatment of haematological complications, such as adverse events from therapy or haematological diseases. In context of the present invention a therapeutic was developed for enhancing haematopoiesis in patients and to support haematopoietic stem cell (HSC) transplantation (HSCT) by administration of periostin compounds to patients or stem cell donors, or by contacting HSC directly with periostin compounds, for example ex vivo, to improve a transplant HSC preparation. The present invention provides periostin derived compounds such as polypeptides, peptides, nucleic acids, and other periostin-derived agents, that are used both in therapeutic applications and for improving haematopoiesis, for example in stem cell donor subjects or to treat HSC in vitro.

The present invention provides pharmaceutical compositions and methods for use in accelerating bone repair and growth and attenuating inflammation-induced osteolysis. In particular, the present invention provides pharmaceutical compositions comprising a peptide comprising the sequence YGFGG for use in treating osteolysis. The present invention further provides pharmaceutical compositions comprising a peptide comprising the sequence YGFGG and CBD for use in accelerating bone repair and / or bone growth in a subject having a bone fracture.

To provide a bone morphogenetic protein-9 (BMP-9) variant in which heterotopic ossification side effect is alleviated, and a fusion thereof.SOLUTION: Provided are a bone morphogenetic protein-9 (BMP-9) variant expressed by a specific amino acid sequence, BMP-9 variant-Fc fusion protein in which an Fc fragment of immunoglobulin is connected to the BMP-9 variant, and a pharmaceutical composition for treating cardiopulmonary disease which contains the BMP-9 variant or the BMP-9 variant-Fc fusion protein as an active ingredient. The cardiopulmonary disease is one or more kinds selected from the group consisting of cardiac infarction, hypertension, pulmonary hypertension, myocardial fibrosis, and pulmonary fibrosis.SELECTED DRAWING: Figure 4b

The present disclosure includes a method of producing a retinal tissue, comprising inducing differentiation of pluripotent stem cells into a retinal tissue on a surface of a culture substrate, wherein the culture substrate comprises a region A and a region B on the surface, the differentiation is induced is the region A, the region A has cell adhesiveness, and the region B is adjacent to at least a part of the region A and has cell adhesiveness lower than the cell adhesiveness of the region A; a retinal tissue produced by the method; and a composition comprising the retinal tissue.

The present invention relates to a BMP-9 variant and a derivative thereof. The variant stimulates endothelial cell-specific signaling, but does not stimulate ectopic ossification-related signaling, as compared to wild-type BMP-9, and thus has the effects of enhancing therapeutic effects on various diseases, including tumors, cardiovascular disease, fibrotic diseases, inflammatory diseases, metabolic diseases, and autoimmune diseases, and reducing side effects.

The invention relates to an mRNA (messenger Ribonucleic Acid) medicine and application thereof in treating pulmonary arterial hypertension. In particular, the present invention relates to polynucleotides encoding peptides comprising a BMP9 active molecule and / or an ACTRIIA ligand trapping agent, lipid nanoparticles comprising said polynucleotides, and therapeutic uses thereof.

A polypeptide or a modifier thereof. The polypeptide or the modifier thereof has the effect of promoting bone formation, and can be used for preventing and / or treating bone diseases.

To provide methods of treating minimal residual cancer in a subject.SOLUTION: The methods involve contacting disseminated cancer cells (DCCs) in a subject with a bone morphogenic protein 7 (BMP7) derivative protein, where the contacting induces or maintains dormancy in the contacted DCCs of the subject to treat minimal residual cancer in the subject. Also disclosed are methods that involve contacting DCCs in a subject with a protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitor selected from LY2, LY3, and LY4, where the contacting eradicates DCCs in the subject to treat minimal residual cancer in the subject.SELECTED DRAWING: None

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

The application provides a bone morphogenetic protein BMP-2 recombinant protein, and the amino acid sequence of the BMP-2 recombinant protein is shown as SEQ ID No. 1. The coding gene, the expression plasmid, the prokaryotic expression vector and the prokaryotic expression method are also disclosed. The prokaryotic expression system is adopted, and a solubilization tag is creatively introduced, so that the inclusion body expression is converted into soluble expression. The BMP-2 is expressed in the form of inclusion body in the prokaryotic system, the protein is converted into soluble expression by adding the solubilization tag, the difficulty of protein separation and purification is reduced, the purification cycle is shortened, and the purification efficiency is improved.

In one aspect, the invention relates to synthetic molecules, compositions and pharmaceutical compositions, which are useful for delivering a bioactive moiety to a site of injury. Also disclosed are methods of treating a tendon injury, methods of treating a fracture, methods of treating a bone stress injury, methods of enhancing incorporation of allograft tissues, methods of promoting repair or regeneration of enthesis tissue during or after an orthopedic surgical procedure, and method of treating osteoporosis, osteoarthritis and / or cartilage defects using the disclosed molecules, compositions and pharmaceutical compositions.

The application provides a method for constructing a Bmp4 gene knock-in mouse model, and the method comprises the following steps: obtaining sgRNA12 shown in SEQ ID NO. 3; mixing the sgRNA12, Cas9 mRNA and a targeting vector shown in SEQ ID NO. 1, and then microinjecting into a mouse zygote to obtain F0 generation mice; selecting F0 generation positive mice in genotype identification results of the F0 generation mice, and mating the F0 generation positive mice with wild type mice to obtain F1 generation mice with stable genotypes; and screening gene targeting mice with correct recombination, and mating the gene targeting mice with retinal specific knock-out tool mice Six3-Cre to obtain Bmp4 gene knock-in model mice. The method has high gene editing efficiency, and the transgenic mouse can highly express human Bmp4 protein.

Provided herein are compositions comprising peptide amphiphiles, soft covalent polymers, and ceramic materials. Composite putty-like materials are provided for medical uses, in particular for the repair of bone / tissue injuries / defects and the regeneration of bone or other tissue.

To provide a composition that significantly improves bone healing and accelerates tissue regrowth.SOLUTION: The present invention provides a chimeric polypeptide that comprises (i) one or more β-tricalcium phosphate (β-TCP)-binding sequence(s), wherein at least one of the one or more β-TCP-binding sequence(s) is selected from the group consisting of specific sequences and (ii) a mammalian growth factor. The present invention also provides a composition containing the chimeric polypeptide.SELECTED DRAWING: Figure 1A

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

This application provides a composition containing PENK protein and its application in promoting osteoblast osteogenic differentiation. Compared with the prior art, this application has the following advantages: The pro-PENK recombinant protein and the PENK-containing composition provided in this application, after being applied to cells with osteogenic potential, enhance osteogenic performance through interaction with CBFB protein, and can significantly promote osteogenic differentiation. Compared with the existing bone morphogenetic protein 2 (BMP recombinant protein), the osteogenic effect is superior. Furthermore, experiments have verified that the osteogenic differentiation effect of pro-PENK recombinant protein on osteoblasts is dose-dependent. This application further verifies that the combined use of low doses of PENK recombinant protein and BMP recombinant protein has a more significant cellular osteogenic effect than the use of either at high doses alone.

The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45Å (Angstroms) or less.

The present invention discloses a method for promoting chondrocyte growth, comprising the following steps: (1) constructing BMP-2 gene recombinant MSC (MSCdBMP2) cells to express BMP-2 protein on the surface of MSCdBMP2 cells; (2) preparing exosomes (MSCdBMP2Exo) derived from MSCdBMP2; (3) stimulating MSCdBMP2 cells and MSCdBMP2Exo to significantly promote chondrocyte growth. The present invention clones the BMP-2 gene into MSC cells through genetic recombination technology to prepare new BMP-2 gene recombinant MSC (MSCdBMP2) cells; at the same time, the exosomes (MSCdBMP2Exo) prepared from MSCdBMP2 cells have a biological function similar to that of MSCdBMP2 cells in promoting chondrocyte growth.

A polypeptide or a modifier thereof having an effect of promoting bone formation; can be used for preventing and / or treating bone diseases.

The instant disclosure relates to methods for converting mammalian definitive endoderm (DE) cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the disclosure relates to formation of esophageal tissue and / or organoids formed from differentiated definitive endoderm.

The present invention discloses a method for constructing a spontaneous ankylosing spondylitis model and its application. The ankylosing spondylitis model is a non-human animal model, and the spontaneous ankylosing spondylitis non-human animal model is constructed by expressing mutant BMP9 protein. The present invention also provides a method for identifying a therapeutic agent for treating ankylosing spondylitis using the spontaneous ankylosing spondylitis non-human animal model. The present invention further provides an application of the spontaneous ankylosing spondylitis non-human animal model in evaluating the efficacy of a therapeutic agent in treating or preventing ankylosing spondylitis.

It is an object of the present invention to provide a novel means for treating a hair cycle-related disease or symptom (hair cycle-related disease etc. Provided is a miR-520d-p polynucleotide or a polynucleotide encoding thereof or a compound for upregulating miR-520d-5p for use in reverting a mutation in a hair cycle-related gene to wild type in a cell, wherein the polynucleotide comprises: (a1) a nucleotide sequence set forth in SEQ ID NO:1: or (a2) a nucleotide sequence having 1 to 3 nucleotide deletions, substitutions, insertions or additions in the nucleotide sequence set forth in SEQ ID NO:1. SEQ ID NO:1 (single-stranded miRNA sequence) 5′-CUACAAAGGGAAGCCCUUUC-3

The present invention provides pharmaceutical compositions and methods for use in accelerating bone repair and growth and attenuating inflammation-induced osteolysis. In particular, the present invention provides pharmaceutical compositions comprising a peptide comprising the sequence YGFGG for use in treating osteolysis. The present invention further provides pharmaceutical compositions comprising a peptide comprising the sequence YGFGG and CBD for use in accelerating bone repair and / or bone growth in a subject having a bone fracture.

To provide human colonic organoids in vitro, usable for determining the efficacy and / or toxicity of potential therapeutics for a disease selected from the group consisting of colitis, colon cancer, polyposis syndrome and / or irritable bowel syndrome.SOLUTION: The disclosure provides a human colonic organoid (HCO), where the human colonic organoid comprises epithelium and mesenchyme and expresses SATB2, MUC2 and / or MUC5B.SELECTED DRAWING: Figure 1A

A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGF1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i) to iii): i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-β (TGF-β) inhibitor.